Clinical trials: active, not recruiting
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03428802
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Rutgers, The State University of New Jersey
Influenza, Influenza-like Illness
A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD
A total of 18,000 eligible subjects (or 6,000 subject distributed evenly between the 3 study arms) will be enrolled. Eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the…
- Conditions
- Influenza, Influenza-like Illness, Influenza Vaccines
- Trial name
- PAIVED (NCT03734237)
- Testing
- Egg based influenza vaccines, Recombinant influenza vaccines, Cell-culture based influenza vaccines
- Where
- 9 sites in United States
- Volunteers
- 15,448 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Non Small Cell Lung Cancer, Lung Cancer, Nonsmall Cell
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
The main purpose of this study is to see if the combination of nivolumab, ipilimumab and nintedanib is effective in people with non- small cell lung cancer.
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer, Nonsmall Cell, Non Small Cell Lung Cancer Metastatic
- Trial name
- NCT03377023
- Testing
- Nivolumab, Ipilimumab, Nintedanib
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Long COVID, Post Acute Sequelae of COVID-19
Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID.
- Conditions
- Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
- Trial name
- PREVAIL-LC (NCT06161688)
- Testing
- Ensitrelvir
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Timothy Henrich
Nonadherence, Patient, Polypharmacy
Pharmacist Intervention to Reduce Post-Hospitalization Utilization
This is a randomized trial testing a peri- and post-discharge pharmacist-led medication management intervention on post-discharge utilization, including both readmissions and emergency department visits within 30 days of…
- Conditions
- Nonadherence, Patient, Polypharmacy, Readmission
- Trial name
- NCT04071951
- Testing
- Pharmacist-led Hospital Discharge Care Intervention
- Where
- 2 sites in United States
- Volunteers
- 6,478 people
- Sponsor
- Cedars-Sinai Medical Center
Peritoneal Cancer, Ovarian Cancer
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.
- Conditions
- Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT02873962
- Testing
- Bevacizumab, Nivolumab, Rucaparib
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Dana-Farber Cancer Institute
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer.
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT01898494
- Testing
- Transoral surgery, intensity-modulated radiation therapy, cisplatin
- Where
- 58 sites in United States
- Volunteers
- 519 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
This study has 2 parts. The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL), The main aim of Part 2 is to learn whether lymphoma disease…
- Trial name
- NCT05020015
- Testing
- TAK-007, Chemotherapy Agents
- Where
- 15 sites in United States
- Volunteers
- 27 people
- Sponsor
- Takeda
Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before surgery.
- Conditions
- Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer
- Trial name
- NCT03433469
- Testing
- Osimertinib, Therapeutic Conventional Surgery
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of California, San Francisco
Thalassemia
A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia
Study AG348-C-010 is a multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of treatment with AG-348 in adult participants with non-transfusion-dependent thalassemia (NTDT).
- Trial name
- NCT03692052
- Testing
- AG-348
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 20 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Breast Cancer
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of disease and relieve some symptoms of cancer.
- Trial name
- NCT03568422
- Testing
- CFI-402257, Paclitaxel
- Where
- 4 sites in Canada
- Volunteers
- 37 people
- Sponsor
- Canadian Cancer Trials Group
Pancreas Cancer
Electrochemotherapy of Posterior Resection Surface for Lowering Disease Recurrence Rate in Pancreatic Cancer (PanECT Study)
The aim of the study is to evaluate toxicity and effectiveness of electrochemotherapy (ECT) with bleomycin in pancreatic cancer in clinical study phase I and II.
- Trial name
- PanECT (NCT04281290)
- Testing
- Electrochemotherapy - electroporation with Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
- Where
- Slovenia
- Volunteers
- 10 people
- Sponsor
- University Medical Centre Ljubljana
Monoclonal Gammopathy, Smoldering Multiple Myeloma
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab
- Trial name
- NCT03236428
- Testing
- Daratumumab
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Digestive System Neoplasm
Perioperative Telemonitoring to Optimize Cancer Care and Outcomes
This study aims to see whether an at-home monitoring program that collects health, symptoms, and quality of life data in real-time can be included as part of the care of surgery patients in order to provide better recovery.
- Trial name
- NCT04986566
- Testing
- Best Practice, Health Education, Medical Device Usage and Evaluation
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- City of Hope Medical Center
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
- Trial name
- NCT02717611
- Testing
- ACP-196 (acalabrutinib)
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Acerta Pharma BV
Prostate Cancer
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
All men following Radical Prostatectomy (RP) at NYU Langone Health undergo routine prostate specific antigen (PSA) testing in order to identify disease recurrence.
- Trial name
- NCT05678322
- Testing
- 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent, PET MRI Imaging
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- NYU Langone Health
Locally Recurrent/Metastatic Triple Negative Breast Cancer
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
The study is being done to find out if the results of a pre-treatment biopsy can predict response to cisplatin and radiation treatment for patients with metastatic or recurrent triple negative breast cancer.
- Trial name
- NCT02422498
- Testing
- external beam radiation therapy, cisplatin, Biopsy of Target Tumor
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hodgkin Disease, Non-Hodgkin Lymphoma
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
The subject has a type of cancer or lymph gland disease associated with a virus called Epstein Barr Virus (EBV), which has come back, is at risk of coming back, or has not gone away after standard treatments.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus, T/NK-lymphoproliferative Disease
- Trial name
- MABEL (NCT02287311)
- Testing
- MABEL CTLs, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
Neurofibromatosis 1, Plexiform Neurofibroma (PN)
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.
- Trial name
- KOMET (NCT04924608)
- Testing
- Selumetinib
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 145 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.